-
公开(公告)号:US20060058512A1
公开(公告)日:2006-03-16
申请号:US11228319
申请日:2005-09-19
IPC分类号: A61K39/395 , C07K16/44
CPC分类号: C07K16/3084 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/462 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.
摘要翻译: 公开了人源化嵌合体抗体,包含人源化嵌合体抗体和药学上可接受的载体的药物组合物,以及治疗癌症的方法,其包括向患者施用药学上可接受量的人源化嵌合体抗体。
-
公开(公告)号:US06965024B2
公开(公告)日:2005-11-15
申请号:US10265713
申请日:2002-10-08
IPC分类号: A61K36/00 , A61K38/00 , A61P35/00 , C07K7/06 , C07K7/08 , C07K14/00 , C07K16/00 , C07K16/18 , C07K16/30 , C07K16/32 , C07K16/46 , C07K19/00 , C12N5/10 , C12N15/00 , C12N15/09 , C12N15/12 , C12N15/13 , C12N15/62 , C12P21/08 , C12R1/91 , C07H21/04
CPC分类号: C07K16/3084 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/462 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of said humanized chimera antibody, are disclosed.
摘要翻译: 人源化嵌合体抗体,包含人源化嵌合体抗体和药学上可接受的载体的药物组合物,以及治疗癌症的方法,其包括向患者施用药学上可接受量的所述人源化嵌合体抗体。
-
公开(公告)号:US06437098B1
公开(公告)日:2002-08-20
申请号:US09225322
申请日:1999-01-05
IPC分类号: C07K1630
CPC分类号: C07K16/3084 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/462 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.
摘要翻译: 公开了人源化嵌合体抗体,包含人源化嵌合体抗体和药学上可接受的载体的药物组合物,以及治疗癌症的方法,其包括向患者施用药学上可接受量的人源化嵌合体抗体。
-
-